Actelion’s Opsumit Ramps Up As Tracleer Patent Loss Gets Closer
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss biotech’s top-selling product Tracleer still accounts for 75% of its sales but Actelion has a strategy that includes launching new PAH therapies and developing a specialty pharma pipeline to cope with the upcoming loss of patent protection.
You may also be interested in...
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
Actelion Grows Its PAH Franchise With Uptravi Approval
Broad label for oral product could help Actelion weather the loss of Tracleer to generic competition.
Actelion Vows To Keep PAH Lead, Despite First-Quarter Dip
Swiss firm blames currency fluctuations and buying patterns for Tracleer and Ventavis sales reductions.